Susquehanna International Group
ANIP icon

Susquehanna International Group’s ANI Pharmaceuticals ANIP Stock Holding History

Susquehanna International Group’s Portfolio ANIP Stock Details ANIP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$500K Sell
6,500
-8,000
-55% -$624K ﹤0.01% 9667
2025
Q4 		$1.14M Sell
14,500
-3,700
-20% -$320K ﹤0.01% 6882
2025
Q3 		$1.67M Sell
18,200
-1,700
-9% -$139K ﹤0.01% 6175
2025
Q2 		$1.3M Buy
19,900
+14,500
+269% +$944K ﹤0.01% 6776
2025
Q1 		$362K Buy
+5,400
New +$323K ﹤0.01% 9649
2024
Q3 		– Sell
-11,600
Closed -$739K – 11890
2024
Q2 		$739K Sell
11,600
-1,200
-9% -$77.9K ﹤0.01% 7289
2024
Q1 		$885K Buy
12,800
+2,900
+29% +$175K ﹤0.01% 7189
2023
Q4 		$546K Sell
9,900
-4,100
-29% -$226K ﹤0.01% 8446
2023
Q3 		$813K Buy
14,000
+4,400
+46% +$254K ﹤0.01% 7110
2023
Q2 		$517K Buy
9,600
+800
+9% +$35.5K ﹤0.01% 8233
2023
Q1 		$350K Sell
8,800
-9,900
-53% -$417K ﹤0.01% 9383
2022
Q4 		$752K Sell
18,700
-900
-5% -$33.8K ﹤0.01% 6820
2022
Q3 		$630K Buy
19,600
+4,000
+26% +$137K ﹤0.01% 7845
2022
Q2 		$463K Sell
15,600
-3,200
-17% -$92.3K ﹤0.01% 8471
2022
Q1 		$528K Sell
18,800
-19,400
-51% -$723K ﹤0.01% 8836
2021
Q4 		$1.76M Buy
38,200
+29,700
+349% +$1.28M ﹤0.01% 5806
2021
Q3 		$279K Buy
8,500
+2,500
+42% +$77.7K ﹤0.01% 10759
2021
Q2 		$210K Sell
6,000
-4,400
-42% -$150K ﹤0.01% 11500
2021
Q1 		$376K Buy
+10,400
New +$326K ﹤0.01% 10122
2020
Q2 		– Sell
-20,000
Closed -$815K – 10066
2020
Q1 		$815K Buy
20,000
+2,600
+15% +$138K ﹤0.01% 5848
2019
Q4 		$1.07M Buy
17,400
+2,300
+15% +$152K ﹤0.01% 5390
2019
Q3 		$1.1M Sell
15,100
-14,700
-49% -$1.1M ﹤0.01% 5496
2019
Q2 		$2.45M Buy
29,800
+5,700
+24% +$405K ﹤0.01% 3782
2019
Q1 		$1.7M Buy
24,100
+12,300
+104% +$724K ﹤0.01% 4020
2018
Q4 		$531K Sell
11,800
-4,700
-28% -$246K ﹤0.01% 5922
2018
Q3 		$933K Sell
16,500
-46,200
-74% -$2.83M ﹤0.01% 5358
2018
Q2 		$4.19M Sell
62,700
-21,600
-26% -$1.35M ﹤0.01% 2942
2018
Q1 		$4.91M Buy
84,300
+43,800
+108% +$2.78M ﹤0.01% 2562
2017
Q4 		$2.61M Buy
40,500
+22,900
+130% +$1.42M ﹤0.01% 3460
2017
Q3 		$924K Buy
17,600
+5,200
+42% +$248K ﹤0.01% 5414
2017
Q2 		$580K Sell
12,400
-13,000
-51% -$627K ﹤0.01% 6365
2017
Q1 		$1.26M Sell
25,400
-5,000
-16% -$281K ﹤0.01% 4651
2016
Q4 		$1.84M Sell
30,400
-41,000
-57% -$2.51M ﹤0.01% 4239
2016
Q3 		$4.74M Sell
71,400
-22,500
-24% -$1.41M ﹤0.01% 2310
2016
Q2 		$5.24M Buy
93,900
+21,700
+30% +$1.05M ﹤0.01% 2137
2016
Q1 		$2.43M Sell
72,200
-118,000
-62% -$4M ﹤0.01% 3399
2015
Q4 		$8.58M Buy
190,200
+115,300
+154% +$4.96M ﹤0.01% 1906
2015
Q3 		$2.96M Sell
74,900
-41,000
-35% -$2.33M ﹤0.01% 3522
2015
Q2 		$7.19M Buy
115,900
+79,600
+219% +$4.74M ﹤0.01% 2412
2015
Q1 		$2.27M Buy
36,300
+31,500
+656% +$1.92M ﹤0.01% 4079
2014
Q4 		$271K Buy
+4,800
New +$212K ﹤0.01% 8296
2014
Q1 		– Sell
-345,100
Closed -$6.93M – 8848
2013
Q4 		$6.93M Buy
345,100
+3,400
+1% +$44.1K ﹤0.01% 2488
2013
Q3 		$3.34M Buy
341,700
+281,000
+463% +$2.02M ﹤0.01% 3319
2013
Q2 		$364K Buy
+60,700
New +$425K ﹤0.01% 6509

Other funds holding ANIP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Susquehanna International Group's ANIP Position: Q1 2026 in Review

Susquehanna International Group increased its ANI Pharmaceuticals (ANIP) stake by 348% in Q1 2026, buying an estimated $3.28M and bringing the position to 54,114 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #4587.

Susquehanna International Group first reported a position in ANIP in Q1 2014 and has held it in 39 quarters since. 280 funds tracked by Wall St. Rank hold ANIP as of Q1 2026.

  • Susquehanna International Group held 54,114 shares of ANI Pharmaceuticals worth $4.16M as of Q1 2026.
  • Susquehanna International Group bought 42,047 ANI Pharmaceuticals shares in Q1 2026, an estimated $3.28M.
  • ANI Pharmaceuticals made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #4587 holding.
  • Susquehanna International Group first reported a position in ANI Pharmaceuticals in Q1 2014 and has held it in 39 quarters since.
  • 280 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.